This recent (2008-2021) study reporting 14 deaths in that period, among other department admissions for some, emergency department admissions, commissions of crimes while under the influence of a benzo, DUI's. Similar data exists for prescribed benzos. Anyhow, Phenazepam was implicated at a moderately higher rate in adverse-events, drug offenses, and deaths. Phenazepam was followed by Flubromazolam, then Flualprazolam, and Etizolam. However, between only 2019-2021, it were Flubromazolam, Flualprazolam, and Etizalom were the most implicated of the designer benzos. There's a difference between rates and tallies. Tallies for lorazepam, clonazepam, and alprazolam would, of course, be higher and yet it would have a lower rate (or likelyhood of causing adverse effects, death, etc). Clonazepam is most definitely a hypnotic. Temazepam and Zolpidem have higher rates of deaths among prescribed benzos I know that for sure. Then they're followed by lorazepam and alprazolam. Though temazepam prescriptions have dropped by up to 60% in some states. Even though I noticed the trend of it around 2011/2012, but scripts dropped dramatically after 2015. You will likely be given trazadone, mirtazpine, quetiapine, zopiclone, zolpidem, or even a low dose diazepam or alprazolam before they start thinking of just handing out a temazepam script. Triazolam saw the same dramatic decline around 2000.
But this is really interesting about phenazepam. Although the number of users was way smaller, it still may have had a slightly higher rate than temazepam. Not sure tho.
But this is really interesting about phenazepam. Although the number of users was way smaller, it still may have had a slightly higher rate than temazepam. Not sure tho.
SourceThe rising use of designer benzodiazepines (DBZD) is a cat-and-mouse game between organized crime and law enforcement. Non-prohibited benzodiazepines are introduced onto the global drug market and scheduled as rapidly as possible by international authorities. In response, DBZD are continuously modified to avoid legal sanctions and drug seizures and generally to increase the abuse potential of the DBZD. This results in an unpredictable fluctuation between the appearance and disappearance of DBZD in the illicit market. Thirty-one DBZD were considered for review after consulting the international early warning database, but only 3-hydroxyphenazepam, adinazolam, clonazolam, etizolam, deschloroetizolam, diclazepam, flualprazolam, flubromazepam, flubromazolam, meclonazepam, phenazepam and pyrazolam had sufficient data to contribute to this scoping review. A total of 49 reports describing 1 drug offense, 2 self-administration studies, 3 outpatient department admissions, 44 emergency department (ED) admissions, 63 driving under the influence of drugs (DUID) and 141 deaths reported between 2008 and 2021 are included in this study. Etizolam, flualprazolam flubromazolam and phenazepam were implicated in the majority of adverse-events, drug offenses and deaths. However, due to a general lack of knowledge of DBZD pharmacokinetics and toxicity, and due to a lack of validated analytical methods, total cases are much likely higher. Between 2019 and April 2020, DBZD were identified in 48% and 83% of postmortem and DUID cases reported to the UNODC, respectively, with flualprazolam, flubromazolam and etizolam as the most frequently detected substances. DBZD toxicology, public health risks and adverse events are reported.